Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or “lot” of Intravenous Immunoglobulin.
North America region is the largest supplier of intravenous immunoglobulin (IVIg), with a production market share nearly 48% in 2016. Europe is the second largest supplier of intravenous immunoglobulin (IVIg), enjoying production market share nearly 23% in 2016.
North America is the largest sales place, with a sales market share nearly 44% in 2016. Following North America, Europe is the second largest sales place with the sales market share of 22%.
Market competition is intense. Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Intravenous Immunoglobulin (IVIg) market is valued at 8120 million US$ in 2017 and will reach 12800 million US$ by the end of 2025, growing at a CAGR of 5.9% during 2018-2025.
Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering
Other regions (Central & South America, Middle East & Africa)
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
By Application, the market can be split into
Request Sample Report and TOC:
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.